Immunohistochemical study on survivin in sinonasal tumors and its relationship with the immunoexpression of Ki67 and Bcl-2

Folia Histochemica et Cytobiologica

Volumn 51, Issue 3, 2013, Pages 225-231

  Stasikowska Kanicka, Olga ^a   Wagrowska Danilewicz, Malgorzata ^a   Danilewicz, Marian ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Bcl 2; Inverted papilloma; Ki67; Sinonasal cancer; Survivin

Indexed keywords

KI 67 ANTIGEN; PROTEIN BCL 2; SURVIVIN;

ADULT; AGED; ARTICLE; CANCER MORPHOLOGY; CARCINOGENESIS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; NOSE CARCINOMA; NOSE POLYP; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SINONASAL INVERTED PAPILLOMA; SQUAMOUS CELL CARCINOMA; UPREGULATION;

IPS;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CELL NUCLEUS; CYTOPLASM; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; KI-67 ANTIGEN; MIDDLE AGED; PAPILLOMA; PARANASAL SINUS NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SINUSITIS;

EID: 84887331605     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2013.0032     Document Type: Article

References (48)

1. Caplan LS, Hall I, Levine RS et al. Preventable risk factors for nasal cancer. Ann Epidemiol. 2000;10:186-191.
2. Weymuller EA, Gal T.J. Neoplasms of the nasal cavity. In: Cummings CW, Flint PW, Harker LA et al. (eds.). Otolaryngology - Head and Neck Surgery. 4th. Elsevier Mosby. Pennsylvania. 2005;1212.
3. Zimmer LA, Carrau RL. Neoplasms of the nose and paranasal sinuses. In: Bailey BJ, Johnson JT, Newland SD, eds. Head & Neck Surgery - Otolaryngology. 4th. Lippincott, Williams & Wilkins. Philadelphia. 2006;417:1480.
4. D'Errico A, Pasian S, Baratti A et al. A case-controlled study on occupational risk factors for sino-nasal cancer. Occup Environ Med. 2009;66:448-455.
5. Barnes L. Schneiderian papillomas and nonsalivary glandular neoplasms of the head and neck. Mod Pathol. 2002;15: 279-297.
6. Von Buchwald C, Bradley PJ. Risks of malignancy in inverted papilloma of the nose and paranasal sinuses. Curr Opin Otolaryngol Head Neck Surg. 2007;15:95-98.
7. Barak Y, Juven T, Haffner R et al. Mdm2 expression is induced by wild type p53 activity. Eur Mol Biol Organ J. 1993;12:461-468.
8. Miyashita T, Krajewski S, Krajewski M et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994;9:1799-1805.
9. Deveraux QL, Reed JC. IPA family proteins: suppressors of apoptosis. Genes Dev. 1999;13:239-252.
10. Adida C, Crotty PL, McGrath J et al. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol. 1998;152:43-49.
11. Fukuda S, Pelus LM. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood. 2001;98:2091-2100.
12. Sah NK, Khan Z, Khan GJ et al. Structural, functional and therapeutic biology of survivin. Cancer Lett. 2006;244: 164-171.
13. Swana HS, Grossman D, Anthony JN et al. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. Lancet. 1999;341:452-453.
14. Yu J, Leung WK, Ebert MPA et al. Increased expression of survivin in gastric cancer patients and in first degree relatives. Br J Cancer. 2002;87:91-97.
15. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917-921.
16. Tanaka K, Iwamoto S, Gon G et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000;6:127-134.
17. Izava A, Kobayashi D, Nasu S et al. Relevance of c-erbB-2, PLU-1 and survivin mRNA expression to diagnostic assessment of breast cancer. Anticancer Res. 2002;22:2965-2969.
18. Rodríguez JA, Span SW, Ferreira CG et al. CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin. Exp Cell Res. 2002;275:44-53.
19. Altieri DC. New wirings in the survivin networks. Oncogene. 2008;27:6276-6284.
20. Mita AC, Mita MM, Nawrocki ST et al. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008;14:5000-5005.
21. Tamm I, Wang Y, Sausville E et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998;58:5315-5320.
22. Uren AG, Wong L, Pakusch M et al. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol. 2000;10: 1319-1328.
23. Bourhis E, Hymowitz SG, Cochran AG. The mitotic regulator Survivin binds as a monomer to its functional interactor Borealin. J Biol Chem. 2007;282:35018-35023.
24. D'Alessandro N, Poma P, Montalto G. Multifactorial nature of hepatocellular carcinoma drug resistance: could plant polyphenols be helpful? World J Gastroenterol. 2007;13:2037-2043.
25. Fortugno P, Wall NR, Giodini A et al. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci. 2002;115:575-585.
26. O'Connor DS, Grossman D, Plescia J et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA. 2000;97:13103-13107.
27. Yang D, Welm A, Bishop JM. Cell division and cell survival in the absence of survivin. Proc Natl Acad Sci USA. 2004;101:15100-15105.
28. Zhao J, Tenev T, Martins LM et al. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci. 2000;113:4363-4371.
29. Barnes L, Everson JW, Reichart P et al. World Health Organization Classification of Tumours. Pathology and Genetics Head and Neck Tumours. IARC Press Lyon. 2005;15-17:28-32.
30. Li F, Yang J, Ramnath N et al. Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer. 2005;114:509-512.
31. Liang J, Gao S, Zhang J et al. Expression of Survivin and Bcl-2 in sinonasal inverted papilloma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009;23:933-935.
32. Lo Muzio L, Pannone G, Leonardi R et al. Survivin, a potential early predictor of tumor progression in the oral mucosa. J Dent Res. 2003;82:923-928.
33. Grabowski P, Kühnel T, Mühr-Wilkenshoff F et al. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer. 2003;88:115-119.
34. Zhang Y, Huang D, Yu G. Survivin expression and its relationship with apoptosis and prognosis in nasal and paranasal sinus carcinomas. Acta Otolaryngol. 2005;125:1345-1350.
35. Wang Y, Kong W, Xiong X et al. The expressions of survivin and VEGF in squamous cell carcinoma of larynx and the correlation between the two marks. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2005;19:838-841.
36. Yin W, Chen N, Zhang Y et al. Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder. Mod Pathol. 2006;19:1487-1497.
37. Ko YH, Roh SY, Won HS et al. Prognostic significance of nuclear survivin expression in resected adenoid cystic carcinoma of the head and neck. Head Neck Oncol. 2010;30:30.
38. Marioni G, Agostini M, Bedin C et al. Survivin and laryngeal carcinoma prognosis: nuclear localization and expression of splice variants. Histopathology. 2012;61:247-256.
39. Katori H, Nozawa A, Tsukuda M. Cell proliferation, apoptosis, and apoptosis inhibition in malignant transformation of sinonasal inverted papilloma. Acta Otolaryngol. 2007;127:540-546.
40. Fan GK, Imanaka M, Yang B et al. Characteristics of nasal inverted papilloma and its malignant transformation: a study of cell proliferation and programmed cell death. Am J Rhinol. 2006;20:360-363.
41. Zheng YF, Chen ZL, Chen HB et al. Expression of survivin, Bcl-2 and p53 during 4-nitro-quinoline 1-oxide-induced rat tongue carcinogenesis. Zhonghua Kou Qiang Yi Xue Za Zhi. 2009;44:168-171.
42. Sun M, Qin Y. Expression of survivin and its correlation with p53 and bcl-2 expression in laryngeal and hypopharyngeal cancer. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2008;22:346-348,351.
43. Bura M, Seiwerth S, Vladika I et al. Possible prognostic significance of p53 and Ki 67 in inverted sinonasal papilloma. Coll Antropol. 2007;31:545-549.
44. Mumbuc S, Karakok M, Baglam T et al. Immunohistochemical analysis of PCNA, Ki67 and p53 in nasal polyposis and sinonasal inverted papillomas. J Int Med Res. 2007;35: 237-241.
45. Gunia S, Liebe D, Koch S. Loss of basal cell keratin 14 reflects increased risk of recurrence in surgically resected sinonasal inverted papilloma. J Clin Pathol. 2008;61:707-712.
46. Hadar T, Shvero J, Yaniv E et al. Human topoisomerase II-alpha is highly expressed in sinonasal-inverted papilloma, but not in inflammatory polyp. J Cell Mol Med. 2008;12: 1551-1558.
47. Kawasaki H, Toyoda M, Shinohara H et al. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer. 2001;91:2026-2032.
48. Li F, Ambrosini G, Chu EY et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1997;396: 580-584.